Navigation Links
Study details genes that control whether tumors adapt or die when faced with p53 activating drugs
Date:5/22/2013

When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even in the face of p53 reactivation create more of the protein p21 than the protein PUMA; tumors that die have more PUMA than p21. And, for the first time, the current study shows a handful of genes that control this ratio.

"The gene p53 is one of the most commonly mutated cancer genes. Tumors turn it off and then they can avoid controls that should kill them. Fine: we have drugs that can reactivate p53. But the bad news is when we go into the clinic with these drugs, only maybe one in ten tumors actually dies. We wanted to know what genes fine-tune this p53 effectiveness," says Joaquin Espinosa, PhD, investigator at the University of Colorado Cancer Center, associate professor in the Department of Molecular, Cellular and Developmental Biology at CU Boulder, and the paper's senior author.

To answer that question, the group including first author Zdenek Andrisyk, PhD, postdoc in the Espinosa Lab, turned off every gene in the human genome in turn and asked if there were genes that, when deactivated, would tip the balance from p21 to PUMA, thus enhancing the likelihood of cell death.

"We found a couple dozen genes involved in this ratio genes that with p53 activated, lead to more p21 and better survival or more PUMA and more cell death," Espinosa says.

The hope is that in addition to drugs that reactivate the tumor-suppressor gene p53, patients could be given a second drug targeting genes that control this p21/PUMA ratio, thus making first drug more effective. Likewise, in cases in which toxicity in healthy tissue limits the use of p53 activating drugs, Espinosa's research could lead to new drugs that thumb the scale of the p21/PUMA ratio toward survival in these healthy tissues. Up or down: learning to adjust the ratio has immense promise.

The group's next step is likely repeating the genetic screen with additional tumor and healthy cell lines to discover which of their newly discovered candidate genes are common controllers of the p21/PUMA ratio across cancer types. And, interestingly, the same technique could be used to make many existing drugs more effective.

"With many of these molecularly targeted therapies, you want one effect but then you end up with many other possible effects," Espinosa says. (An example is the recently-reported side effect of low testosterone in male lung cancer patient taking the molecularly targeted drug crizotinib.) The genetic screening technique used in the Espinosa lab could help disentangle effect from side effect showing which secondary genes regulate the desired, tumor-killing response and which secondary genes lead to undesirable side-effects.

"Not only could this technique lead to drugs that decrease the side effects of targeted therapies, but if you're not limited by these side effects, you can simply give more drug, perhaps making existing drugs much more powerful," Espinosa says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... Soquel, California (PRWEB) , ... May 24, 2017 , ... If you are thinking of ... you are interested in business architecture, October is the perfect time to visit. , Business ... as an à la carte offering for individuals, as a 4-½ day package for individuals, ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... most prominent for-profit and nonprofit hospitals and health systems in the nation and ... around their institutions, led professional organizations and been instrumental in developing successful hospital ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... fluoride (PVDF) based sleep diagnostics sensors, announced today it had completed the first ... of a mix of domestic and rest of world (ROW) authorized dealers specializing ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Allegheny ... to open The Alexis Joy D’Achille Center for Women’s Behavioral Health at West ... available in western Pennsylvania for women suffering from pregnancy-related depression. Construction of the ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of ... Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on Health & Human ... the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017  The ... Clinical and Scientific Meeting— OBP Medical , a leading ... announced the launch of a new extra-small size and ... ER-SPEC vaginal specula. Already available in small, ... sizes makes OBP Medical,s line of single-use lighted specula ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
Breaking Medicine Technology: